The Lancet publishes results from phase III program evaluating Rinvoq in atopic dermatitis. - AbbVie.
The results were published in two separate manuscripts as part of the May 22, 2021 issue of The Lancet. The publication of Measure Up 1 and Measure Up 2 shares efficacy and safety results of patients treated with upadacitinib (15 mg or 30 mg, once daily) monotherapy versus placebo for 16 weeks. The publication of AD Up shares efficacy and safety results of patients treated with either dose of Rinvoq met all primary and secondary endpoints. See- "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials"..Emma Guttman-Yassky, MD,Henrique D Teixeira, PhD, Eric L Simpson, MD, Kim A Papp, MD, Aileen L Pangan, MD Andrew Blauvelt, MD et al.-Published:May 20, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00588-2. " Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial".- Prof Kristian Reich, MD , Henrique D Teixeira, PhD, Marjolein de Bruin-Weller, MD, Prof Thomas Bieber, MD, Weily Soong, MD ,Prof Kenji Kabashima, MD ,et al.Published:May 20, 2021DOI:https://doi.org/10.1016/S0140-6736(21)00589-4.
Related news and insights
AbbVie announced the FDA has approved Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended.
Pfizer Inc. announced that FDA approved Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of adults living with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
LEO Pharma announced that the FDA has approved Adbry (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.